Loading stock data…
Bioventus Inc. (BVS)
$11.80+0.32 (+2.79%)
Market ClosedLast close Jul 24
Bioventus Inc., a medical device company, focuses on relieving pain and addressing musculoskeletal therapies in the United States and internationally.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Bioventus Inc. in the Healthcare sector is trading at $11.80 with a market capitalization of $579M. Wall Street consensus targets $14.80 (5 analysts), implying a +25.4% move over the next 12 months. The stock is currently near its 52-week high of $12.53, remaining 36.1% above its 200-day moving average. On fundamentals, Piotroski 8/9 indicates strong financial quality, Altman Z in the distress zone. The Whystock Score of 95/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +25.4% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $132.09M↓ | $157.90M↑ | $138.65M↓ | $147.66M↑ | $123.88M |
| Gross Profit | $90.77M↓ | $108.78M↑ | $94.23M↓ | $102.09M↑ | $83.06M |
| Operating Income | $8.87M↓ | $21.72M↑ | $11.25M↓ | $18.37M↑ | $4.95M |
| Net Income | $3.11M↓ | $14.76M↑ | $3.15M↓ | $7.46M↑ | -$2.64M |
Peer Comparison
JNJUNHPFE
Fundamentals
Bioventus Inc., a medical device company, focuses on relieving pain and addressing musculoskeletal therapies in the United States and internationally. The company's product portfolio includes pain treatments, which comprise various intra-articular an...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$579.25M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
20.85
Beta
Defensive asset. Lower volatility than the S&P 500.
0.72
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
15.08%
Volume
Today's trading volume
464,346
Recent News
Does Bioventus (BVS) Have the Potential to Rally 28.92% as Wall Street Analysts Expect?
The consensus price target hints at a 28.9% upside potential for Bioventus (BVS). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Bioventus (BVS) Upgraded to Buy: Here's Why
Bioventus (BVS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Should Value Investors Buy Bioventus (BVS) Stock?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Bioventus (BVS) Stock Looks Overvalued On Earnings Yet Backed By Broader Checks
After a strong three year share price run, Bioventus now screens as overvalued on market multiples, while its broader valuation checks point to a more nuanced picture rather than a clear bubble or a clear bargain. Bioventus has returned about 234.6% over the past three years, which puts recent valuation concerns in the context of a stock that has already delivered very strong gains for existing shareholders. Recent positive sentiment around earnings expectations can support the current...
Are Medical Stocks Lagging Caribou Biosciences (CRBU) This Year?
Here is how Caribou Biosciences, Inc. (CRBU) and Bioventus (BVS) have performed compared to their sector so far this year.